Literature DB >> 29674510

Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive.

V Craig Jordan1.   

Abstract

Predictive tests, to refine the estrogen receptor assay, for the adjuvant treatment of breast cancer with tamoxifen and oral selective estrogen receptor degraders (SERD) are required. A splice variant of the corepressor NCOR2, BQ2313636.1 predicts tamoxifen resistance to adjuvant tamoxifen and AZ9496, the first oral SERD, completes phase I studies. Clin Cancer Res; 24(15); 3480-2. ©2018 AACRSee related articles by Gong et al., p. 3681 and Hamilton et al., p. 3510. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29674510      PMCID： PMC6082682          DOI： 10.1158/1078-0432.CCR-18-0759

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  13 in total

1.  Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.

Authors:  M M Gottardis; S P Robinson; P G Satyaswaroop; V C Jordan
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

2.  3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats.

Authors:  T M Willson; B R Henke; T M Momtahen; P S Charifson; K W Batchelor; D B Lubahn; L B Moore; B B Oliver; H R Sauls; J A Triantafillou
Journal:  J Med Chem       Date:  1994-05-27       Impact factor: 7.446

3.  Structural basis for an unexpected mode of SERM-mediated ER antagonism.

Authors:  Ya-Ling Wu; Xiaojing Yang; Zhong Ren; Donald P McDonnell; John D Norris; Timothy M Willson; Geoffrey L Greene
Journal:  Mol Cell       Date:  2005-05-13       Impact factor: 17.970

4.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.

Authors:  C K Osborne; J Pippen; S E Jones; L M Parker; M Ellis; S Come; S Z Gertler; J T May; G Burton; I Dimery; A Webster; C Morris; R Elledge; A Buzdar
Journal:  J Clin Oncol       Date:  2002-08-15       Impact factor: 44.544

Review 5.  Tamoxifen: catalyst for the change to targeted therapy.

Authors:  V Craig Jordan
Journal:  Eur J Cancer       Date:  2008-01       Impact factor: 9.162

6.  Response after withdrawal of tamoxifen and progestogens in advanced breast cancer.

Authors:  A Howell; D J Dodwell; H Anderson; J Redford
Journal:  Ann Oncol       Date:  1992-09       Impact factor: 32.976

7.  AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

Authors:  Hazel M Weir; Robert H Bradbury; Mandy Lawson; Alfred A Rabow; David Buttar; Rowena J Callis; Jon O Curwen; Camila de Almeida; Peter Ballard; Michael Hulse; Craig S Donald; Lyman J L Feron; Galith Karoutchi; Philip MacFaul; Thomas Moss; Richard A Norman; Stuart E Pearson; Michael Tonge; Gareth Davies; Graeme E Walker; Zena Wilson; Rachel Rowlinson; Steve Powell; Claire Sadler; Graham Richmond; Brendon Ladd; Ermira Pazolli; Anne Marie Mazzola; Celina D'Cruz; Chris De Savi
Journal:  Cancer Res       Date:  2016-03-28       Impact factor: 12.701

8.  A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.

Authors:  Ping Fan; Fadeke A Agboke; Heather E Cunliffe; Pilar Ramos; V Craig Jordan
Journal:  Eur J Cancer       Date:  2014-09-06       Impact factor: 9.162

9.  Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.

Authors:  M M Gottardis; S Y Jiang; M H Jeng; V C Jordan
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

10.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321
View more
  2 in total

Review 1.  Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health.

Authors:  Balkees Abderrahman; V Craig Jordan
Journal:  Endocrinology       Date:  2018-08-01       Impact factor: 4.736

2.  The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients.

Authors:  Katharina Pachmann; Stefan Schuster
Journal:  Cancers (Basel)       Date:  2018-10-29       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.